Tekes Funding for a New TUTLI-project
BioMediTech received 480.000 Eur Tekes funding for a two year (1.1.2016–31.12.2017) TUTLI-project in late December 2015.
In this project scientists of the institute led by Professor Pasi Kallio (TUT) take the development of miniaturized hypoxia (low oxygen concentration) cabinet innovation further and study the commercialization of the idea into new business. The existing commercial laboratory cabinets used for making low oxygen concentration incubation environment have high investments and running costs, and they are clumsy, stationary hardware. The minihypoxy solution is a mobile low-cost piece of equipment that brings hypoxia environment available for every cell research laboratory. A proof-of-concept system will be designed and tested at the University of Turku at the hypoxia laboratory team supervised by Dr Panu Jaakkola. The project comprises of a profound analysis of markets, marketing options and business models conducted by the BioMediTech resources and its partners.
Further information available from: Juha Laiho, Project Manager, juha.laiho (at) biomeditech.fi
BioMediTech Cancer Researchers Got Research Funding
Professors Matti Nykter and George Bova from BioMediTech at the University of Tampere both got 100 000 Euro grants from Suomen Syöpäsäätiö (Finnish Cancer Foundation) and Suomen Syöpäyhdistys (Finnish Cancer Association) in their autumn 2015 round. FiDiPro professor Bova’s research group concentrates on the molecular tracing of metastases in prostate cancer, and Professor Nykter’s group investigates the mutations of chromatine in prostate cancer.
Professor Anne Kallioniemi got 25 000 Euro grant for her project ”Bone morphogenetic protein 4 in”.
Associate Professor, Docent Marko Pesu got 25 000 Euros for his project “The effect of the FURIN proteasis in T cells on the immune response in cancer”
Doctoral Student, MSc Minna Ampuja got 3 500 Euros for her dissertation project ”The effect of BMP4 on the prostate cancer pathogenesis”.
The Finnish cancer orgnisations have supported cancer research in Finland with altogether 5.8 Million Euros in 2015.
BioMediTech Fortifies Its European Connections
BioMediTech has made a service contract with a Belgian BioVille company incubator. The contract offers BioMediTech help in international commercialization and BioVille’s networks. In addition, BioMediTech will also have an office in Belgium. There are over 140 bioindustry operators in the Flanders area. –The contract gives us new partners and financing possibilities, says Programme Manager Juho Väisänen from BioMediTech. -We aim to enhance cooperation with the whole area, as there is a short distance to e.g. Brussels, Leuven, Maastricht and Eindhoven. Regenerative medicine is especially interesting for foreign companies, says Väisänen.
More Information from: Programme Manager Juho Väisänen, juho.vaisanen (at) biomeditech.fi
Team Copla Wins Slush 2015 Science Pitching Competition
Slush Science Pitching Competition was held in Helsinki, Finland on November 12th. We are proud to announce that the Winner was team Copla who has developed a biodegradable scaffold that can be used to fix cartilage damage. The researchers in the team are from BioMediTech and University of Helsinki. The team is now looking for business partners to take their invention further.
Signatures of Chaotic and Stochastic Dynamics Uncovered with ε-recurrence Networks
BioMediTech researchers recently published a paper in Proceedings of the Royal Society A, where they propose the applicability of local and global ε-recurrence network measures to distinguish between chaotic and stochastic dynamics using paradigmatic model systems such as the Lorenz system, and the chaotic and hyper-chaotic Rössler system. They also demonstrate the effect of increasing levels of noise on these network measures and provide a real-world application of analysing electroencephalographic data comprising epileptic seizures. Their results show that both local and global ε-recurrence network measures are sensitive to the presence of unstable periodic orbits and other structural features associated with chaotic dynamics that are otherwise absent in stochastic dynamics. These network measures are still robust at high noise levels and short data lengths. Read the whole article.
Researchers at BioMediTech Developed a New Software Tool, CytoSpectre
Orientation and the degree of isotropy are important in many biological systems such as the fibrillar structures of the cytoskeleton. Researchers at BioMediTech developed a new software tool, CytoSpectre, which allows quantitative, repeatable analysis of these properties based on micrographs. The software was applied to human stem cell derived cardiomyocytes in order to better understand the effects of physical stimulation on the cells. CytoSpectre is compatible with images obtained using most microscopy techniques and can be operated on basic hardware via a graphical user interface.
The software is freely available at www.tut.fi/cytospectre. Read the article describing the new tool published in the open access, peer-reviewed journal BMC Bioinformatics.
Human Pluripotent Stem Cells Offer a New Approach for Corneal Reconstruction
Limbal stem cell deficiency, caused by lack of functional limbal epithelial stem cells (LESCs), is a debilitating eye disease characterized by loss of corneal clarity and visual impairment. LESCs derived from human pluripotent stem cells offer a novel approach for corneal reconstruction, yet careful evaluation of these cells is important before proceeding towards clinical applications. In this study, mass spectrometry-based proteomics technique was used to compare these cells to their native counterparts. Read the article published in Scientific Reports by BioMediTech researchers in collaboration with School of Medicine (University of Tampere) and University of Szeged, Hungary.
Cell Mechanics Are More Complex than Previously Thought
Cell mechanics are considerably more complex than previously thought and may affect cell structures at various levels. This finding is based on a collaborative research project conducted by an international research team from ETH Zurich and BioMediTech, involving Teemu Ihalainen, a postdoctoral researcher at the Academy of Finland. The project was characterised by an interdisciplinary approach which combined cellular and molecular biology with research on biomaterials. The findings of the team were published in the Nature Materials online publication.
Global Regenerative Medicine Market Shows Strong Growth
The market for human spare parts is growing rapidly. While the market is still relatively small worldwide, all the indicators are pointing up. BioMediTech’s seminar brought together scientists and companies to discuss the latest developments in the field.
”From a consumer perspective, examples of the most intriguing innovations being adopted by the healthcare sector are a novel method for determining whether a particular cardiac medication will be effective in an individual patient and new stem cell-based treatments for incontinence. In the field of eye research, we’re currently testing new methods for retinal repair through cell transplantation, Professors Minna Kellomäki and Heli Skottman from BioMediTech say.
Adult and Stem Cell-derived Cardiac Cells Respond Similarly to Selective Current Blockers
Cardiac safety has always been a critical issue and expensive part in the drug development process. The integration of two new technologies, i.e. in vitro experiments on cardiac cells derived from human stem cells and in silico – computational – experiments by means of human ventricular models, holds the promise to dramatically change the cardiotoxicity assessment of new drugs.
BioMediTech researchers found out that adult and stem cell-derived cardiac cells respond similarly to selective current blockers, but sometimes with different sensitivities. E.g. for the L-type calcium current or for the inward rectifier potassium current. This result is good news for the use of stem cell derived-cardiac cells as such over-sensitivity can be used to ease the identification of desired or adverse drug effects. Moreover, this is a clear example of how predictions, obtained through in silico models, can actively support the pharmacological research. Read the article published in British Journal of Pharmacology.
BioMediTech Annual Report 2014
BioMediTech Annual Report 2014 has been published. Read the annual report here.